Huahai Pharmaceutical (600521.SH) subsidiary received a refund of $14.2296 million in customs duties from the United States.

China Fortune Financial APP News, Huahai Pharmaceutical (600521.SH) announced that in February 2026, the Supreme Court of the United States ruled that the government's imposition of tariffs under the International Emergency Economic Powers Act (IEEPA) exceeded its statutory authority. Consequently, the related tariff measures are invalid from the beginning, and the tariffs already collected must be refunded to the importers. The US Customs and Border Protection (CBP) officially began the refund process on April 20, 2026. As of now, the Company's subsidiary, Shouke Health, has received a total refund of $14.2296 million in US tariffs, accounting for 36.36% of the Company's net profit attributable to the shareholders of the listed company in the most recent audited period.